Home » Stocks » RGLS

Regulus Therapeutics Inc. (RGLS)

Stock Price: $1.07 USD -0.20 (-15.75%)
Updated Mar 4, 2021 2:09 PM EST - Market open
Market Cap 84.96M
Revenue (ttm) 5.02M
Net Income (ttm) -19.30M
Shares Out 38.14M
EPS (ttm) -0.68
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 4
Last Price $1.07
Previous Close $1.27
Change ($) -0.20
Change (%) -15.75%
Day's Open 1.23
Day's Range 1.05 - 1.26
Day's Volume 1,568,916
52-Week Range 0.42 - 1.97

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 43 minutes ago

Regulus (RGLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRNewsWire - 3 weeks ago

LA JOLLA, Calif., Feb. 10, 2021 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting...

PRNewsWire - 1 month ago

LA JOLLA, Calif., Jan. 27, 2021 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting...

PRNewsWire - 1 month ago

LA JOLLA, Calif., Jan. 5, 2021 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting ...

GuruFocus - 2 months ago

Billionaire investor Steven Cohen (Trades, Portfolio) disclosed earlier this week his firm, Point72 Asset Management, established a 14.37% stake in Regulus Therapeutics Inc. (NASDAQ:RGLS) and ...

Other stocks mentioned: ALNA
Zacks Investment Research - 2 months ago

Investors need to pay close attention to Regulus Therapeutics (RGLS) stock based on the movements in the options market lately.

PRNewsWire - 2 months ago

LA JOLLA, Calif., Dec. 8, 2020 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting ...

PRNewsWire - 3 months ago

MINNEAPOLIS, Dec. 2, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and Regulus Therapeutics (NASDAQ: RGLS) announced a collaboration to support Regulus with biomarker analysis for...

Other stocks mentioned: TECH
Zacks Investment Research - 3 months ago

Regulus (RGLS) delivered earnings and revenue surprises of 80.00% and 880.39%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

PRNewsWire - 3 months ago

LA JOLLA, Calif., Nov. 5, 2020 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting ...

Zacks Investment Research - 4 months ago

Regulus (RGLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRNewsWire - 4 months ago

LA JOLLA, Calif., Nov. 2, 2020 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting ...

PRNewsWire - 4 months ago

LA JOLLA, Calif., Oct. 15, 2020 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting...

PRNewsWire - 4 months ago

LA JOLLA, Calif., Oct. 13, 2020 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS) (the "Company" or "Regulus"), a biopharmaceutical company focused on the discovery and development of i...

PRNewsWire - 5 months ago

LA JOLLA, Calif., Sept. 11, 2020 /PRNewswire/ -- Regulus Therapeutics Inc.

PRNewsWire - 6 months ago

LA JOLLA, Calif., Sept. 3, 2020 /PRNewswire/ -- Regulus Therapeutics Inc.

PRNewsWire - 6 months ago

LA JOLLA, Calif., Aug. 31, 2020 /PRNewswire/ -- Regulus Therapeutics Inc.

Zacks Investment Research - 6 months ago

Regulus (RGLS) delivered earnings and revenue surprises of -9.52% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

PRNewsWire - 6 months ago

LA JOLLA, Calif., Aug. 13, 2020 /PRNewswire/ -- Regulus Therapeutics Inc.

Zacks Investment Research - 6 months ago

Regulus (RGLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRNewsWire - 6 months ago

LA JOLLA, Calif., Aug. 6, 2020 /PRNewswire/ -- Regulus Therapeutics Inc.

PRNewsWire - 7 months ago

LA JOLLA, Calif., Aug. 3, 2020 /PRNewswire/ -- Regulus Therapeutics Inc.

PRNewsWire - 7 months ago

LA JOLLA, Calif., July 29, 2020 /PRNewswire/ -- Regulus Therapeutics Inc.

PRNewsWire - 7 months ago

LA JOLLA, Calif., July 22, 2020 /PRNewswire/ -- Regulus Therapeutics Inc.

PRNewsWire - 9 months ago

LA JOLLA, Calif., May 14, 2020 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting ...

Zacks Investment Research - 9 months ago

Regulus (RGLS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 11 months ago

Regulus (RGLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

Regulus (RGLS) delivered earnings and revenue surprises of 10.34% and -10.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Regulus (RGLS) delivered earnings and revenue surprises of 50.00% and -99.28%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Regulus (RGLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

Regulus (RGLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

About RGLS

Regulus Therapeutics, a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States. Its two lead product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS4326, an anti-miR targeting miR-17, which is in Phase Ib clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developin... [Read more...]

Industry
Biotechnology
IPO Date
Oct 4, 2012
CEO
Joseph Hagan
Employees
24
Stock Exchange
NASDAQ
Ticker Symbol
RGLS
Full Company Profile

Financial Performance

In 2019, RGLS's revenue was $6.83 million, an increase of 9,388.89% compared to the previous year's $72,000. Losses were -$18.59 million, -61.83% less than in 2018.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for RGLS stock is "Hold." The 12-month stock price forecast is 1.33, which is an increase of 24.30% from the latest price.

Price Target
$1.33
(24.30% upside)
Analyst Consensus: Hold